Baxter marketing option Intercept-ed, may precede U.S. kick-off
This article was originally published in The Gray Sheet
Executive Summary
Cerus will pay $39 mil to Baxter to re-acquire rights to Intercept blood pathogen inactivation system for red cell applications in the U.S. and plasma applications in the U.S. and Canada, under a restructured co-marketing agreement announced Feb. 3. Baxter will continue working with Cerus to bring Intercept to the European market for platelet and plasma applications through at least 2006. The firms will continue to work together on U.S. regulatory approval of platelet applications...